Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

47 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Evaluation of two short standardised regimens for the treatment of rifampicin-resistant tuberculosis (STREAM stage 2): an open-label, multicentre, randomised, non-inferiority trial.
Goodall RL, Meredith SK, Nunn AJ, Bayissa A, Bhatnagar AK, Bronson G, Chiang CY, Conradie F, Gurumurthy M, Kirenga B, Kiria N, Meressa D, Moodliar R, Narendran G, Ngubane N, Rassool M, Sanders K, Solanki R, Squire SB, Torrea G, Tsogt B, Tudor E, Van Deun A, Rusen ID; STREAM study collaborators. Goodall RL, et al. Lancet. 2022 Nov 26;400(10366):1858-1868. doi: 10.1016/S0140-6736(22)02078-5. Epub 2022 Nov 8. Lancet. 2022. PMID: 36368336 Free PMC article. Clinical Trial.
Virological and immunological outcomes at 3 years after starting antiretroviral therapy with regimens containing non-nucleoside reverse transcriptase inhibitor, protease inhibitor, or both in INITIO: open-label randomised trial.
INITIO Trial International Co-ordinating Committee; Yeni P, Cooper DA, Aboulker JP, Babiker AG, Carey D, Darbyshire JH, Floridia M, Girard PM, Goodall RL, Hooker MH, Mijch A, Meiffredy V, Salzberger B. INITIO Trial International Co-ordinating Committee, et al. Among authors: goodall rl. Lancet. 2006 Jul 22;368(9532):287-98. doi: 10.1016/S0140-6736(06)69074-0. Lancet. 2006. PMID: 16860698 Clinical Trial.
Prevalence, incidence, and associated risk factors of tuberculosis in children with HIV living in the UK and Ireland (CHIPS): a cohort study.
Turkova A, Chappell E, Judd A, Goodall RL, Welch SB, Foster C, Riordan A, Shingadia D, Shackley F, Doerholt K, Gibb DM, Collins IJ; Collaborative HIV Paediatric Study (CHIPS) Steering Committee. Turkova A, et al. Among authors: goodall rl. Lancet HIV. 2015 Dec;2(12):e530-9. doi: 10.1016/S2352-3018(15)00200-3. Epub 2015 Oct 29. Lancet HIV. 2015. PMID: 26614967
Restoration of anti-tetanus toxoid responses in patients initiating highly active antiretroviral therapy with or without a boost immunization: an INITIO substudy.
Burton CT, Goodall RL, Samri A, Autran B, Kelleher AD, Poli G, Pantaleo G, Gotch FM, Imami N; INITIO Trial International Co-ordinating Committee. Burton CT, et al. Among authors: goodall rl. Clin Exp Immunol. 2008 May;152(2):252-7. doi: 10.1111/j.1365-2249.2008.03611.x. Clin Exp Immunol. 2008. PMID: 18410636 Free PMC article. Clinical Trial.
High level of viral suppression and low switch rate to second-line antiretroviral therapy among HIV-infected adult patients followed over five years: retrospective analysis of the DART trial.
Kityo C, Gibb DM, Gilks CF, Goodall RL, Mambule I, Kaleebu P, Pillay D, Kasirye R, Mugyenyi P, Walker AS, Dunn DT; DART Trial Team. Kityo C, et al. Among authors: goodall rl. PLoS One. 2014 Mar 13;9(3):e90772. doi: 10.1371/journal.pone.0090772. eCollection 2014. PLoS One. 2014. PMID: 24625508 Free PMC article. Clinical Trial.
The virological durability of first-line ART among HIV-positive adult patients in resource limited settings without virological monitoring: a retrospective analysis of DART trial data.
Dolling DI, Goodall RL, Chirara M, Hakim J, Nkurunziza P, Munderi P, Eram D, Tumukunde D, Spyer MJ, Gilks CF, Kaleebu P, Dunn DT, Pillay D; DART Virology Group. Dolling DI, et al. Among authors: goodall rl. BMC Infect Dis. 2017 Feb 21;17(1):160. doi: 10.1186/s12879-017-2266-3. BMC Infect Dis. 2017. PMID: 28222702 Free PMC article.
Residual activity of two HIV antiretroviral regimens prescribed without virological monitoring.
Dunn DT, Goodall RL, Munderi P, Kityo C, Ranopa M, Bacheler L, Van Houtte M, Gilks C, Kaleebu P, Pillay D; DART Virology and Trial Team. Dunn DT, et al. Among authors: goodall rl. Antimicrob Agents Chemother. 2011 Oct;55(10):4575-80. doi: 10.1128/AAC.00580-11. Epub 2011 Jul 18. Antimicrob Agents Chemother. 2011. PMID: 21768516 Free PMC article. Clinical Trial.
Viral rebound and emergence of drug resistance in the absence of viral load testing: a randomized comparison between zidovudine-lamivudine plus Nevirapine and zidovudine-lamivudine plus Abacavir.
Ndembi N, Goodall RL, Dunn DT, McCormick A, Burke A, Lyagoba F, Munderi P, Katundu P, Kityo C, Robertson V, Yirrell DL, Walker AS, Gibb DM, Gilks CF, Kaleebu P, Pillay D; Development of Antiretroviral Treatment in Africa Virology Group and Trial Team. Ndembi N, et al. Among authors: goodall rl. J Infect Dis. 2010 Jan 1;201(1):106-13. doi: 10.1086/648590. J Infect Dis. 2010. PMID: 19938977 Clinical Trial.
47 results